2021 American Transplant Congress
The Tumor-suppressor Signaling of the α1-na/k-atpase- Cav-1-src Complex at the Caveola in Nash Related Hepatocellular Carcinoma
*Purpose: Hepatocellular Carcinoma (HCC) is the 2nd and fastest-growing cause of cancer related mortality worldwide, mainly from the metabolic cellular disturbances promoted by the epidemic…2020 American Transplant Congress
Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond UCSF Criteria: Tumor Biology Not the Tumor Number Decide the Long Term Outcome- A Single Center Retrospective Analysis of Using Extended Criteria
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: HCC is the fifth most common cancer and the third most frequent cause of cancer deaths worldwide. After its introduction for LT in HCC…2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…2020 American Transplant Congress
Performance of the Retreat Score in Predicting Post-Transplant Hepatocellular Carcinoma Recurrence at a Large Academic Center
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: Post-transplant hepatocellular carcinoma recurrence (R-HCC) results in poor outcomes. The RETREAT score was recently derived to predict HCC recurrence, incorporating pre-transplant alpha fetoprotein and…2020 American Transplant Congress
The Oncological Optimal Tacrolimus Target Level after Liver Transplant for Hepatocellular Carcinoma
1The Cleveland Clinic, Cleveland, OH, 2Duke University, Durham, NC, 3Chiba University, Chiba, Japan
*Purpose: The recurrence rate after liver transplant (LT) for hepatocellular carcinoma (HCC) is high as 15-20% nevertheless of complete removal of tumor and carcinogenic liver.…2020 American Transplant Congress
Multiple Downstaging Episodes for Hepatocellular Carcinoma Prior to Liver Transplant Increases Risk of Post-Transplant HCC Recurrence
Henry Ford Hospital, Detroit, MI
*Purpose: Early-stage Hepatocellular Carcinoma (HCC) is best managed with liver transplantation (LT). Several studies have shown that patients meeting Milan or successfully downstaged to meet…2020 American Transplant Congress
National Experience with Living Donor Liver Transplant for Hepatocellular Carcinoma
1Dept of Medicine, UCSF, San Francisco, CA, 2Dept of Surgery, UCSF, San Francisco, CA
*Purpose: LDLT is an attractive option to decrease both wait time and risk of waitlist dropout in HCC. This study aimed to evaluate temporal and…2020 American Transplant Congress
HCC Liver Transplantation Waitlist Dropout Rates before and after the Mandated Six-Month Wait-Time
*Purpose: Studies have shown significant improvement in hepatocellular carcinoma (HCC) recurrence rates following the UNOS implementation of a six-month wait period. However, few have examined…2020 American Transplant Congress
Comparing Post-Transplant Outcomes in Living and Deceased Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: An Analysis of UNOS Registry
*Purpose: Because of possible short waiting time, living donor liver transplantation (LDLT) for HCC may provide survival benefit compared to deceased donor LT (DDLT). This…2020 American Transplant Congress
Living Donor Liver Transplantation Should Be Considered Cautiously in Recurrent Hepatocellular Carcinoma within the Milan Criteria after Curative Liver Resection
*Purpose: Insufficient data are available about patient survival following different treatments for recurrent hepatocellular carcinoma (HCC) after primary hepatectomy. We retrospectively evaluated the effects of…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 23
- Next Page »